On April 25, 2016 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, reported the submission of an Investigational New Drug (IND) Application for TSR-022 to the U.S. Food and Drug Administration (Press release, TESARO, APR 25, 2016, View Source [SID:1234511378]). Schedule your 30 min Free 1stOncology Demo! TSR-022 is a monoclonal antibody drug candidate targeting TIM-3.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"TSR-022 is poised to be the second antibody candidate from our immuno-oncology portfolio to begin clinical studies," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Following clearance of the IND, we plan to begin a Phase 1 study in mid-2016."
About TSR-022
TSR-022 is a monoclonal antibody candidate targeting TIM-3 and was developed as part of a collaboration between TESARO and AnaptysBio, Inc. This collaboration was initiated in March of 2014, and is focused on the development of monospecific antibody drug candidates targeting PD-1 (TSR-042), TIM-3 (TSR-022), and LAG-3, and bi-specific antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3, in addition to a novel bispecific antibody candidate designed to target undisclosed targets.